Last C$1.93 CAD
Change Today +0.055 / 2.94%
Volume 1.0M
PLI On Other Exchanges
Symbol
Exchange
OTC US
Toronto
Frankfurt
As of 2:36 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

prometic life sciences inc (PLI) Snapshot

Open
C$1.86
Previous Close
C$1.87
Day High
C$1.98
Day Low
C$1.84
52 Week High
11/18/14 - C$2.21
52 Week Low
12/18/13 - C$0.83
Market Cap
1.0B
Average Volume 10 Days
1.9M
EPS TTM
C$-0.03
Shares Outstanding
532.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROMETIC LIFE SCIENCES INC (PLI)

Related News

No related news articles were found.

prometic life sciences inc (PLI) Related Businessweek News

No Related Businessweek News Found

prometic life sciences inc (PLI) Details

ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparation, plasma-derived therapeutics, and small-molecule drugs. The company also offers its technologies for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutics products targeting unmet medical needs in the fields of fibrosis, anemia, cancer, and autoimmune disease, as well as plasma-derived therapeutics in orphan drug indications. It operates in two segments, Therapeutics and Protein Technology. The Therapeutics segment’s lead product includes PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. This segment also develops PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases; and PBI-1402, a drug candidate for the treatment of anemia indications. The Protein Technology segment provides plasma protein purification system, a solution for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology for various biopharmaceutical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.

Founded in 1992

prometic life sciences inc (PLI) Top Compensated Officers

Chief Executive Officer, President and Non-In...
Total Annual Compensation: C$435.0K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: C$322.3K
Chief Executive Officer of ProMetic BioScienc...
Total Annual Compensation: C$238.5K
General Counsel and Corporate Secretary
Total Annual Compensation: C$197.0K
Senior Vice President of Product & Asia Pacif...
Total Annual Compensation: C$283.6K
Compensation as of Fiscal Year 2013.

prometic life sciences inc (PLI) Key Developments

ProMetic Life Sciences Inc. Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Revenue Guidance for the Second Half of 2014

ProMetic Life Sciences Inc. reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenues of $2.3 million compared to $6.0 million for the third quarter ended September 30, 2013. The company generated a net loss of $20.7 million compared to a net loss of $5.3 million for the quarter ended September 30, 2013. Total revenues for the nine months ended September 30, 2014 were $12.5 million compared to $15.6 million during the comparative 2013 period, a decrease of $3.1 million. The company generated net loss of $5.9 million compared to a net loss of $9.9 million for the nine months period ended September 2013. The net loss generated is mainly due to the loss on the fair value variation of the warrant liability and the increase in non-rechargeable R&D expenses, notably the investment in the Laval plant and PBI-4050 clinical program. The company's yearly product sales should continue slightly ahead of last year and the fourth quarter anticipated licensing revenues should largely compensate as demonstrated by the reiteration of its revenue guidance for the second half of 2014 of over $15 million.

ProMetic Life Sciences Inc.'s PBI-4050 Clears to Commence Clinical Trials in Patients with Diabetic Kidney Disease

ProMetic Life Sciences Inc. announced that its small molecule lead compound PBI-4050 has been approved to commence clinical trials in patients suffering from Diabetic Kidney Disease following the CTA clearance by Health Canada. In the initial phase of the clinical program scheduled to commence this month, eight DKD patients will be enrolled. The objectives of this double blind, placebo controlled, multi-dose study are to demonstrate the safety and tolerability of PBI-4050 and to compare the pharmacokinetic profile of the drug in DKD patients with severely impaired kidney function to that demonstrated in healthy volunteers. This short study will immediately be followed by a placebo-controlled multicentre trial in DKD patients. The company also expects to initiate a clinical program this quarter in patients suffering from Idiopathic Pulmonary Fibrosis. PBI-4050 is an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in several in vivo experiments targeting fibrosis. Fibrosis is a very complex process by which continuing inflammation causes vital organs to lose their function as normal tissue is replaced by fibrotic scar tissue. The proof of concept data generated to date confirms lead drug candidates anti-fibrotic activity in several key organs including the kidneys, the heart, the lungs and the liver.

ProMetic Life Sciences Inc. to Report Q3, 2014 Results on Nov 13, 2014

ProMetic Life Sciences Inc. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Standard Time on Nov 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLI:CN C$1.93 CAD +0.055

PLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLI.
View Industry Companies
 

Industry Analysis

PLI

Industry Average

Valuation PLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 54.5x
Price/Book 32.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 53.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROMETIC LIFE SCIENCES INC, please visit www.prometic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.